SUFU 2019: Transcutaneous Posterior Tibial Nerve Stimulation in Female Patients with Overactive Bladder: A Prospective Single-Center Cohort

Miami, FL (UroToday.com) Benoit Peyronnet, MD has presented research on transcutaneous tibial nerve stimulation in women with overactive bladder (OAB). The goal of the study was to assess the effectiveness of such conservative therapy in female cohort presented at the University of Rennes from 2013 to 2018.

Women with overactive bladder were instructed on how to use a transcutaneous-PTNS at home by an experienced nurse. Each participant was asked to complete a 20-minute session per day for a duration of 3 months. Maintenance treatment option of daily 20-minutes was offered to those who responded to the initial therapy. Dr. Peyronnet and colleagues evaluated following criteria: participants’ perception of symptom improvement based on the visual analogic scale (0 to 10) and discontinuation rate. In addition, change in Urinary symptom profile score, the number of urinary incontinence episodes and maximum voided volume were estimated as secondary outcome measures.

The sample size included 62 females with and without a diagnosis of overactive bladder (85.5% has reported UI and 14.5% of participants didn’t report any urinary symptoms). Baseline urodynamics showed that the majority of study participants had detrusor overactivity (71.1%) and failed previous antimuscarinic therapy (67.7%). Data analysis demonstrated that the mean impression of improvement was 4.8 ( at 3-month follow up (Figure 1). While mean voided volume have increased from 309.2 ( 213.3) ml (p=0.02), the number of OAB episodes has decreased from 4.9 to 3.4 per day (p=0.002).

UroToday SUFU2019 Transcutaneous Posterior Tibial Nerve Stimulation 1
Figure 1

46.9% of participants have discontinued study therapy at 12-week follow up assessment (Figure 2).
UroToday SUFU2019 Transcutaneous Posterior Tibial Nerve Stimulation 2
Figure 2

The study showed that transcutaneous-PTNS is effective in the treatment of OAB in females. Future research is needed to estimate the safety and cost-effectiveness of this line of therapy compared to percutaneous-PTNS.

Presented by: Benoit Peyronnet, MD, The University of Rennes

Co-authors: Nelly Senal, MD, Quentin Alimi, MD, Lorene Mathieu, MD, Juliette Hascoet, MD, Isabelle Bonan, MD Ph.D., Andrea Manunta, MD, Jacqeues Kerdraon, MD
University of Rennes

Written by: Hanna Stambakio, BS, Clinical Research Coordinator, Division of Urology, University of Pennsylvania, Twitter: @AStambakio at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting, SUFU 2019, February 26 - March 2, 2019, Miami, Florida

Edited by: Susan Small, RPh, Digital Science Press, Inc.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe